QC
TLX

Quadrature Capital’s Telix Pharmaceuticals TLX Stock Holding History

Quadrature Capital’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
+102,425
New +$1.04M 0.01% 684
2026
Q1 		– Sell
-36,828
Closed -$276K – 1968
2025
Q4 		$276K Buy
+36,828
New +$354K ﹤0.01% 876

Other funds holding TLX

PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Quadrature Capital's TLX Position: Q2 2026 in Review

Quadrature Capital opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 102,425 shares worth $1.18M. The stake represents 0.01% of the portfolio and ranks #684 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in TLX as recently as Q4 2025.

Quadrature Capital first reported a position in TLX in Q4 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Quadrature Capital held 102,425 shares of Telix Pharmaceuticals worth $1.18M as of Q2 2026.
  • Telix Pharmaceuticals was a new Quadrature Capital position in Q2 2026.
  • Telix Pharmaceuticals made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #684 holding.
  • Quadrature Capital first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.